Suchergebnisse - "2494G1JF75"

PubPharm (985)

21

A comparison of the long-term durability of nevirapine, efavirenz and lopinavir in routine clinical practice in Europe : a EuroSIDA study

enthalten in: HIV medicine | 2011

von Reekie, J. | Reiss, P. | Ledergerber, B. | +108

22

Lopinavir/ritonavir dosing during pregnancy in Brazil and maternal/infant laboratory abnormalities

enthalten in: The Brazilian journal of infectious diseases : an official publication of the Brazilian Society of Infectious Diseases | 2011

von Peixoto, M. | Pilotto, J. | Stoszek, S. | +7

23

Low level determinations of methyl methanesulfonate and ethyl methanesulfonate impurities in Lopinavir and Ritonavir Active pharmaceutical ingredients by LC/MS/MS using electrospray ionization

enthalten in: Journal of pharmaceutical and biomedical analysis | 2011

von Kakadiya, P. | Reddy, B. | Singh, V. | +3

24

Combination antiretroviral therapy as treatment for human immunodeficiency virus-associated mucosa-associated lymphoid tissue type lymphoma of the nasopharynx

enthalten in: Internal medicine journal | 2011

von Varma, R. | Carroll, S. | Jacobson, I. | +2

25

Lipid and lipoprotein profile in HIV-infected patients treated with lopinavir/ritonavir as a component of the first combination antiretroviral therapy

enthalten in: AIDS research and human retroviruses | 2011

von Magenta, L. | Dell-Kuster, S. | Richter, W. | +63

26

Phase II trial of ritonavir/lopinavir in patients with progressive or recurrent high-grade gliomas

enthalten in: Journal of neuro-oncology | 2011

von Ahluwalia, M. | Patton, C. | Stevens, G. | +9

27

GS-8374, a novel HIV protease inhibitor, does not alter glucose homeostasis in cultured adipocytes or in a healthy-rodent model system

enthalten in: Antimicrobial agents and chemotherapy | 2011

von Hruz, P. | Yan, Q. | Tsai, L. | +4

28

Cost-effectiveness of atazanavir/ritonavir compared with lopinavir/ritonavir in treatment-naïve human immunodeficiency virus-1 patients in Sweden

enthalten in: Scandinavian journal of infectious diseases | 2011

von Thuresson, P. | Heeg, B. | Lescrauwaet, B. | +3

29

Trial in youngest group points to HIV treatment overhaul

enthalten in: Nature medicine | 2011

von Dolgin, E.

30

Low lopinavir plasma or hair concentrations explain second-line protease inhibitor failures in a resource-limited setting

enthalten in: Journal of acquired immune deficiency syndromes (1999) | 2011

von van Zyl, G. | van Mens, T. | McIlleron, H. | +9